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Background: In esophageal cancer (EC) patients who are not eligible for surgery, definitive chemoradiation (dCRT) with
curative intent using cisplatinum with 5-fluorouracil (5-FU) is the standard chemotherapy regimen. Nowadays carboplatin/
paclitaxel is also often used. In this study, we compared survival and toxicity rates between both regimens.
Patients and methods: This multicenter study included 102 patients treated in five centers in the Northeast
Netherlands from 1996 till 2008. Forty-seven patients received cisplatinum/5-FU (75 mg/m2 and 1 g/m2) and 55 patients
carboplatin/paclitaxel (AUC2 and 50 mg/m2).
Results: Overall survival (OS) was not different between the cisplatinum/5-FU and carboplatin/paclitaxel group
{[P = 0.879, hazard ratio (HR) 0.97 [confidence interval (CI) 0.62–1.51]}, with a median survival of 16.1 (CI 11.8–20.5) and
13.8 months (CI 10.8–16.9). Median disease-free survival (DFS) was comparable [P = 0.760, HR 0.93 (CI 0.60–1.45)]
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between the cisplatinum/5-FU group [11.1 months (CI 6.9–15.3)] and the carboplatin/paclitaxel group [9.7 months (CI
5.1–14.4)]. Groups were comparable except clinical T stage was higher in the carboplatin/paclitaxel group (P = 0.008).
High clinical T stage (cT4) was not related to OS and DFS in a univariate analysis (P = 0.250 and P = 0.201). A higher per-
centage of patients completed the carboplatin/paclitaxel regimen (82% versus 57%, P = 0.010). Hematological and non-
hematological toxicity (≥grade 3) in the carboplatin/paclitaxel group (4% and 18%) was significantly lower than in the
cisplatinum/5-FU (19% and 38%, P = 0.001).
Conclusions: In this study, we showed comparable outcome, in terms of DFS and OS for carboplatin/paclitaxel com-
pared with cisplatinum/5-FU as dCRT treatment in EC patients. Toxicity rates were lower in the carboplatin/paclitaxel
group together with higher treatment compliance. Carboplatin/paclitaxel as an alternative treatment of cisplatinum/5-FU
is a good candidate regimen for further evaluation.
Key words: esophageal, cancer, carboplatin, paclitaxel, definitive, chemoradiation
introduction
With an increasing incidence and overall 5-year survival of
about 15%, the prognosis of esophageal cancer (EC) patients
remains poor [1–4]. In patients treated surgically with curative
intent, 5-year survival rates are usually between 25% and 39%.
In an attempt to improve prognosis, multimodality treatment
has been incorporated during the last two decades. Neoadjuvant
chemoradiation has shown to be superior compared with
surgery alone with a gain of 12%–15%, leading to be the current
standard procedure in medically fit patients with curative resect-
able esophageal carcinoma [5, 6].
In patients who are not eligible for curative intended surgery,
due to a close relation of the tumor with- or tethered to vital
structures (aorta, trachea, especially the higher lesions) or
patients otherwise medically unfit for surgical resection, defini-
tive chemoradiation (dCRT) has to be considered as an alterna-
tive option. The RTOG 85-01 trial showed that in patients
not receiving surgery, chemoradiation with cisplatinum and
5-fluorouracil (5-FU) improved 5-year survival up to 26% com-
pared with patients receiving only radiotherapy (RT) [7, 8].
Several chemotherapy regimens are currently being used as
definitive regimen in EC patients. The most commonly used
regimens are those consisting of cisplatinum in combination
with 5-FU or paclitaxel combined with carboplatin. Current
guidelines in the United States and Europe recommend the
combination of cisplatinum with 5-FU as standard combined
with 50.4 Gy radiation therapy [9], while the carboplatin/pacli-
taxel regimen is frequently used in patients with extensive co-
morbidity [10]. Cisplatinum has a high-toxicity profile and
carboplatin is an often used alternative in platinum-based
therapy regimens. However, no study has yet investigated the su-
periority of one of these regimens in overall survival (OS) in
patients receiving dCRT.
The aim of this study was to compare the differences in survival
and toxicity rates between cisplatinum with 5-FU and carboplatin
with paclitaxel as dCRT in a relatively large homogenous cohort
of EC patients treated in Northeast Netherlands.
patients andmethods
patients
In this multicenter retrospective study, we analyzed 102 EC patients without
distant metastases, who were treated with curatively intended dCRT in five
centers in the Northeast Netherlands from 1996 till 2008. This subgroup of
patients treated with only chemoradiation as definitive treatment is part of a
larger cohort described elsewhere [11]. As described in the publication of
Smit et al., the indications in both dCRT regimens were technically unresect-
able tumors, medically unfit patients or patient’s own choice. Carboplatin/
paclitaxel was the standard regimen in two of the five centers and also pre-
ferred above cisplatinum/5-FU for patients with cardiovascular comorbidity.
Patients with other histology than adenocarcinoma or squamous carcinoma
were excluded as well as cases with missing relevant staging information or
inadequate follow-up.
methods
pretreatment staging. Pretreatment staging consisted of endoscopic
ultrasonography (EUS) with fine needle aspiration of suspected lymph
nodes, 16–64 multidetector computed tomography (md-CT) scans of the
neck, chest and abdomen and on indication cervical echographic
examination. From 2002 onward, 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET) was added to the staging procedure. Bronchoscopy
was required when the tumor was tethered to the trachea or main stem
bronchus. Patients were staged according to the Union for International
Cancer Control TNM 6th edition [12].
chemotherapy regimens. The cisplatinum/5-FU dCRT (N = 47)
regimen consisted of cisplatinum 75 mg/m2 (day 1) and 5-FU 1 g/m2 (day
1–4) at week 1 and 5 during RT, with two additional courses on week 8 and
11 (RTOG 85-01 scheme) [7].
In the carboplatin/ paclitaxel group (N = 55), a chemotherapy scheme was
given weekly during RT at day 1, 8, 15, 22, 29 (and 35). The paclitaxel dose
was 50 mg/m2 and carboplatin was administered at AUC2.
radiation scheme. RT planning was carried out after direct simulation,
based on diagnostic images or 3D based on treatment planning CT images.
During direct simulation, patients had to swallow barium contrast to
facilitate identification and localization of the primary tumor. For the
planning CT, the patients also received oral contrast.
Gross tumor volume (GTV), defined as the macroscopic primary tumor
and regional lymph node metastases, was reconstructed using all available
information derived from endoscopy, EUS, CT and from FDG-PET.
At direct simulation, margins from GTV to field margin were 5 cm in
caudal/cranial direction and 2 cm margin in transversal plane. A margin of
4 cm in caudal/cranial direction and 1.5 cm in transversal plane was used to
generate the planning target volume. If the treatment planning was based on
a planning CT, the clinical target volume was obtained by adding a 3-cm
margin in cranial–caudal direction and 1 cm margin in transversal plane.
A 0.5–1 cm margin was used around pathological lymph nodes.
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A total radiation dose of 46.8–70 Gy (median dose 50.4 Gy) was given in
daily fractions of 1.8–2 Gy. One patient received a dose of 41.1 Gy as the
initial neoadjuvant treatment was switched to dCRT. Generally delivered
with at least 6 MV photons. Intraluminal brachytherapy was given in two
fractions of 6 Gy or a single fraction of 10 Gy and administered in 5% of the
patients.
data acquisition. Data was obtained using the medical records of the
different centers in the North-East region of the Netherlands. Additional
information from comprehensive cancer centers was acquired. The study was
carried out according to national ethics guidelines (www.ccmo-online.nl).
follow-up. Patients were generally seen for regular follow-up according
to national guidelines at 4–8 weeks after completion of treatment, every
6 months in the first year and thereafter annually up to 5 years or until death.
toxicity. Toxicity was measured according to the Common Terminology
Criteria for Adverse Events (CTCAE 4.0). Grade 3 and 4 toxicity reactions
are shown in Table 3. Grade 5 toxicity occurring up to 30 days after
treatment was recorded as mortality.
statistics. OS was defined as the time interval between the starting date of
the chemoradiation and documentation of the day of death or last follow-up.
Disease-free survival (DFS) was determined from the starting date of
treatment to documented date of first recurrence or death of any cause. OS
and DFS rates were calculated according to the Kaplan–Meier method and
compared using the log-rank test. Patient characteristics and toxicity rates
were determined and compared using Student’s t-test and Fisher’s exact test.
Univariate and multivariate analyses were carried out using Cox-regression
analyses. P values of <0.150 in the univariate analysis were included in the
multivariate analysis. A P value of <0.05 [95% confidence interval (CI)] was
considered as significant. The statistical analyses were carried out by using
the Statistical Package for Social Sciences (SPSS, Chicago, IL) version 18.0
software.
results
patient and tumor characteristics
Patient characteristics are shown in Table 1. Age (P = 0.169), sex
(P = 0.468) and WHO-performance (P = 0.334) did not differ
Table 1. Clinical and patient characteristics
Cisplatinum/5-FU (N = 47) Carboplatin/paclitaxel (N = 55) P value
Age (mean, years) 62.5 64.8 0.169*
Sex (m/f) 39 (83%)/8 (17%) 42 (76%)/13 (24%) 0.468
cT1 0 (0%) 1/47 (2%) 0.008
cT2 3/46 (7%) 2/47 (4%)
cT3 31/46 (67%) 18/47 (38%)
cT4 12/46 (26%) 26/47 (55%)
cN1 (%) 39/47 (83%) 41/54 (76%) 0.465
cM1a (%) 11/47 (23%) 5/54 (9%) 0.061
Histology (AC/SCC) 28 (60%)/19 (40%) 23 (42%)/32 (58%) 0.112
Tumor length >5 cm 25/36 (69%) 27/38 (71%) 1.000
Tumor site
Upper 9/44 (21%) 14/54 (26%) 0.050
Mid 4/44 (9%) 10/54 (19%)
Distal 22/44 (50%) 28/54 (52%)
GEJ 9/44 (21%) 2/54 (4%)
WHO performance
0–1 45/47 (96%) 47/54 (87%) 0.334
2 2/47 (4%) 5/54 (9%)
3 0 (0%) 2/54 (4%)
Radiation dose
<50.0 Gy 1 (2%) 2 (4%) 0.062
50.0–50.4 Gy 42 (89%) 53 (96%)
>50.4 Gy 4 (9%) 0 (0%)
Comorbidity present 23/47 (49%) 30/55 (55%) 0.691
Cardiovascular and pulmonary comorbidity 9/47 (19%) 21/55 (38%) 0.049
Type of comorbidity
None 24/47 (51%) 25/55 (46%) 0.048
Pulmonary 1/47 (2%) 9/55 (16%)
Cardiovascular 8/47 (17%) 12/55 (22%)
Other 14/47 (30%) 9/55 (16%)
*Student’s t-test, all other variables were compared using a Fisher’s exact test.
GEJ, gastroesophageal junction.
TNM classification according to sixth edition.
P < 0.05 was considered significant, significant values presented in italics.
original articles Annals of Oncology
 | Honing et al. Volume 25 | No. 3 | March 2014
among both groups. In both groups, comorbidity was equally
present, 49% in the cisplatinum/5-FU group and 55% in the car-
boplatin/paclitaxel group (P = 0.691). The type of comorbidity
varied between the groups as the carboplatin/paclitaxel group
had more cardiovascular and pulmonary comorbidity (38%)
compared with the cisplatinum/5-FU group (19%, P = 0.049).
Of the tumor characteristics, localization differed with more gas-
troesophageal junction tumors in the cisplatinum with 5-FU
group (P = 0.05). Clinical T stage did differ (P = 0.008) with a T3
stadium of 67% in the cisplatinum/5-FU group, while the
majority of patients in the carboplatin/paclitaxel group (55%)
had a higher stage group T4. N Stage (P = 0.465) was compar-
able between both groups. A higher percentage of patients in
the cisplatinum with 5-FU group had a cM1a stage (23%) com-
pared with the paclitaxel with carboplatin group which was not
significant (9%, P = 0.061). Most patients received a radiation
dose of 50–50.4 Gy in both treatment groups and the distribu-
tion of radiation dose did not differ between the hospitals
(P = 0.181).
overall survival and disease-free survival
OS was comparable between the cisplatinum with 5-FU group
and the carboplatin with paclitaxel group [P = 0.879, HR 0.97
(CI 0.62–1.51)], with a median survival of, respectively, 16.1 (CI
11.8–20.5) and 13.8 (CI 10.8–16.9) months (Figure 1A). DFS
was also not significantly different [P = 0.76, HR 0.93 (CI 0.60–
1.45)]. Median DFS was 11.1 in the cisplatinum with 5-FU
group (Figure 1B, CI 6.9–15.3) and 9.7 months with carboplatin
with paclitaxel (CI 5.1–14.4). OS and DFS were also not differ-
ent between both chemotherapy regimens when analyzed for
the two histological subtypes, adenocarcinoma and squamous
cell carcinoma (supplementary Figure S2, available at Annals of
Oncology online). As the Kaplan–Meier survival curves cross,
the proportional hazards criterion for the log-rank test is not
met. Therefore, we also tested smaller groups (OS and DFS
24 months) in the ESCC group for both regimens and found
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Figure 1. Kaplan–Meier survivals estimation of the overall survival (A) and disease-free survival (B) for dCRT with cisplatinum/5-FU (N = 47) or carboplatin
/paclitaxel (N = 55).
Table 2. Multivariate Cox-regression analysis
Multivariate analysis HR (95% CI) P value
OS (N = 97)
Chemotherapy regimen 1.00 (0.61–1.64) 0.990
Comorbidity presenta 0.67 (0.39–1.13) 0.135
Localization 0.149
Upper 0.62 (0.25–1.57) 0.314
Mid 1.49 (0.57–3.87) 0.418
Distal 1.20 (0.52–2.75) 0.669
GEJ Reference
Completed chemotherapy 1.28 (0.73–2.24) 0.388
DFS (N = 96)
Chemotherapy regimen 0.89 (0.54–1.47) 0.641
Comorbidity present 0.78 (0.46–1.32) 0.357
cN 0.63 (0.32–1.22) 0.168
Localization 0.301
Upper 0.90 (0.35–2.34) 0.829
Mid 1.61 (0.62–4.16) 0.330
Distal 1.59 (0.70–3.65) 0.270
GEJ Reference
Completed chemotherapy 1.45 (0.82–2.56) 0.198
aDue to the large number of subgroups, comorbidity was only
included as dichotomous variable.
GEJ, gastroesophageal junction.
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univariate and multivariate cox-regression analysis
Chemotherapy regimen was not related to OS and DFS in a uni-
variate analysis (HR = 0.97, P = 0.879 and HR = 0.93, P = 0.760).
Other factors as comorbidity, localization and completion of the
chemotherapy were significantly related to OS (supplementary
Table S2, available at Annals of Oncology online, P = 0.031,
P = 0.028 and P = 0.046). Comorbidity, tumor localization, cN
stage and completion of chemotherapy were related to DFS
(P = 0.107, P = 0.014, P = 0.114, P = 0.123). When corrected for
these factors in a multivariate Cox-regression analysis, OS and
DFS did not change drastically for chemotherapy regimen
[Table 2, P = 0.990, HR 1.00 (CI 0.61–1.64) and P = 0.641, HR
0.89 (CI 0.54–1.47)]. None of the other factors were an inde-
pendent prognostic factor for OS or DFS.
toxicity and mortality
Table 3 shows the treatment compliance and toxicity grades.
A higher percentage of patients with carboplatin/paclitaxel com-
pleted their treatment compared with the cisplatinum/5-FU
group (82% versus 57%, P = 0.010). The occurrence of side
events was significantly lower in the carboplatin/paclitaxel
group compared with the cisplatinum/5-FU group (P = 0.001).
In the cisplatinum/5-FU group, 38% (N = 18/47) experienced a
grade 3 toxicity and 15% (N = 7/47) a grade 4 toxicity. In the
carboplatin/paclitaxel group, toxicity rates were lower, 15%
(N = 8/55) experienced a grade 3 toxicity and 6% (N = 3/55) a
grade 4 toxicity. Hematologic toxicity was most common and
higher in the cisplatinum/5-FU group (19% versus 4%,
P = 0.021). Nonhematologic adverse events were also more
common in the cisplatinum/5-FU group (38% versus 18%,
P = 0.028).
In the cisplatinum/5-FU group, two patients died due to treat-
ment-related events. One patient had atrial fibrillation resulting
in brain infarction and death. The other patient developed
severe bone marrow depletion and died from neutropenic sepsis
based on a pneumonia. In the carboplatin/paclitaxel group, one
patient with previous hepatocellular carcinoma died due to liver
failure and severe diarrhea.
discussion
In this study, we described comparable outcomes in terms of OS
and DFS between EC patients treated with cisplatinum/5-FU
and with carboplatin/paclitaxel as part of dCRT. Severe toxicity
rates including hematological and nonhematological events
(both ≥grade 3) were significantly lower for the carboplatin/
paclitaxel group (P = 0.001). Furthermore, a significantly higher
percentage of patients completed their therapy in the carbopla-
tin with paclitaxel group which could be due to fewer and
milder adverse events (P = 0.010). However, completion of
chemotherapy was not an independent prognostic factor for OS
or DFS in a multivariate analysis.
Literature concerning the effectiveness and side-effects of car-
boplatin with paclitaxel compared with standard cisplatinum
with 5-FU is limited. Supplementary Table S3, available at
Annals of Oncology online gives an overview of the literature
reporting on one or both of the schemes in dCRT in EC. Polee
et al. [13] were the first to show the use of carboplatin with
paclitaxel as dCRT scheme in a phase I study. Median survival
was 11 months, and myelotoxicity was regarded acceptable as
only 5% of the 77% with neutropenia developed fever. Wang
et al. [14] showed a good response rate in a small group of EC
patients with locally advanced disease (N = 16) treated with
dCRT with carboplatin and paclitaxel with an overall 3-year sur-
vival rate of 60%. However, they do not compare this regimen
with other chemotherapy regimens. Courrech Staal et al. [15]
compared carboplatin with paclitaxel and cisplatinum with
5-FU, in both a curative dCRT and a neoadjuvant setting. The
median OS was 15 months for the dCRT group (N = 49), which
is similar as to our study. No survival distinction was made
between the two therapy regimens in this study. A recent study
of Blom et al. [16] compared cisplatinum/5-FU and carboplatin/
paclitaxel in the neoadjuvant setting in EC patients and showed
comparable overall toxicity (≥grade 3) as in our study and no
difference in survival.
Toxicity rates for the carboplatin with paclitaxel group of our
study were comparable with the rates in the CROSS trial. In
our study, 4% of patients experienced hematological events
Table 3. Treatment compliance and major toxicities
Cisplatinum/











26 (55%)a 12 (22%) 0.001
Hematological
≥grade 3
9 (19%) 2 (4%) 0.021
Nonhematological
≥grade 3
18 (38%) 10 (18%) 0.028
Grade 3 18 (38%) 8 (15%) 0.011
Grade 4 7 (15%) 3 (6%) 0.180
Mortality 2 (4%) 1 (2%) 0.594
Hematologicb
Febrile leucopenia 6 (13%) 2 (4%) 0.139
Trombocytopenia 1 (2%) 2 (4%) 1.000
Bleeding 1 (2%) 0 (0%) 0.461
Anemia 3 (6%) 3 (6%) 1.000
Nonhematologicb
Nauseau/vomiting 2 (4%) 0 (0%) 0.210
Fatigue 1 (2%) 0 (0%) 0.461
Diarrhea 0 (0%) 1 (2%) 1.000
Mucositis 2 (4%) 2 (4%) 1.000
Other 14 (30%) 7 (13%) 0.049
Compared using Fisher’s exact test.
aIn cisplatinum/5-FU group, one patient had both a grade 3
hematological toxicity as a grade 4 nonhematological toxicity.
bAll recorded toxicity.
P < 0.05 was considered significant, significant values presented in
italics.
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(≥grade 3) and 18% nonhematological events (≥grade 3) com-
pared with 7.6% and 13%, respectively, in the CROSS trial [6].
Our study is limited by the number of patients included and
the retrospective design. An important limitation is that patients
were not randomized, which could lead to differences in patient
characteristics and treatment per hospital between both treat-
ment groups. Between our groups, we showed no differences in
outcome but a larger number of patients would be required to
make these conclusions more robust. A phase III trial would be
suitable for that purpose. However, the number of EC patients
receiving dCRT is limited, and we do not expect groups to
become significant with larger numbers. As toxicity rates are
lower in the carboplatin/paclitaxel group an evaluation of the
quality of life would also be of interest in future studies.
Another important difference between our groups is that
patients in the carboplatin/paclitaxel group had more cardiovas-
cular and pulmonary comorbidity. This could suggest a possible
selection bias to include patients in better physical condition in
the cisplatinum/5-FU group. However, most patients (78%) re-
ceiving carboplatin/paclitaxel were treated in the two centers
were this was the standard regimen thereby arguing against a se-
lection bias.
In conclusion, the present study suggests that OS and DFS are
similar in both treatment regimens in dCRT in EC. Carboplatin
with paclitaxel has fewer adverse events with higher treatment
compliance. These results suggest carboplatin/paclitaxel could
be used as an alternative for cisplatinum/5-FU in dCRT for EC
patients which should be further evaluated.
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